Guangdong Taien Kang Pharmaceutical Co., Ltd.
2025 Annual Board of Directors Work Report
In 2025, the Board of Directors of Guangdong Taien Kang Pharmaceutical Co., Ltd. (hereinafter referred to as "Taien Kang" or "the Company") strictly adhered to the "Company Law of the People's Republic of China" (hereinafter referred to as "Company Law"), the "Securities Law of the People's Republic of China" (hereinafter referred to as "Securities Law"), and other relevant laws and regulations, as well as the "Articles of Association of Guangdong Taien Kang Pharmaceutical Co., Ltd." (hereinafter referred to as "Articles of Association") and other relevant regulations. The Board conscientiously fulfilled its duties and responsibilities, diligently implemented all resolutions of the shareholders' meetings, and actively promoted the development of the Company's various businesses and standardized corporate governance. The 2025 work report of the Board of Directors is as follows:
I. Overview of the Company's Operations in 2025
(I) Review of the Company's Operations During the Reporting Period
In 2025, the Company achieved an operating revenue of 67,489.68 million yuan, a year-on-year decrease of 6.40%; and a net profit attributable to shareholders of the listed company of 28.6329 million yuan, a year-on-year decrease of 73.54%. Affected by the continuous increase in competing products and fierce market competition, sales revenue from the sexual health business declined, but the trend of market demand gradually warming up has been observed. During the reporting period, sales revenue was 15,388.73 million yuan, a year-on-year decrease of 13.47%. Due to insufficient production capacity of the Thai manufacturer and delays in imported goods falling short of expectations, the sales revenue of "He Wei Zheng Chang Wan" declined, reaching 17,195.57 million yuan during the reporting period, a year-on-year decrease of 16.64%. The ophthalmology drug business maintained a stable trend, with sales revenue of 18,335.96 million yuan during the reporting period, a year-on-year decrease of 0.66%. On the cost side, the Company increased investment in R&D and brand promotion, reaching brand promotion cooperation agreements with platforms such as Focus Media, Xiaohongshu, and Meituan. Advertising and business promotion expenses in 2025 reached 10,937.72 million yuan, a year-on-year increase of 66.09%, which compressed profit margins.